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Ectopic expression of oncogenes such as Ras induces expression of p19
Arf, which, in turn, activates p53 and growth
arrest. Here, we used a multistage model of squamous cell carcinoma development to investigate the functional
interactions between Ras, p19
Arf, and p53 during tumor progression in the mouse. Skin tumors were induced in wild-
type, p19
Arf-deficient, and p53-deficient mice using the DMBA/TPA two-step protocol. Activating mutations in Hras
were detected in all papillomas and carcinomas examined, regardless of genotype. Relative to wild-type mice, the
growth rate of papillomas was greater in p19
Arf-deficient mice, and reduced in p53-deficient mice. Malignant
conversion of papillomas to squamous cell carcinomas, as well as metastasis to lymph nodes and lungs, was markedly
accelerated in both p19
Arf- and p53-deficient mice. Thus, p19
Arf inhibits the growth rate of tumors in a p53-
independent manner. Through its regulation of p53, p19
Arf also suppresses malignant conversion and metastasis. p53
expression was upregulated in papillomas from wild-type but not p19
Arf-null mice, and p53 mutations were more
frequently seen in wild-type than in p19
Arf-null carcinomas. This indicates that selection for p53 mutations is a direct
result of signaling from the initiating oncogenic lesion, Hras, acting through p19
Arf.
Citation: Kelly-Spratt KS, Gurley KE, Yasui Y, Kemp CJ (2004) p19
Arf suppresses growth, progression, and metastasis of Hras-driven carcinomas through p53-dependent and
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Introduction
Tumor development and metastasis is a multistep process
of somatic cell evolution that includes uncontrolled prolifer-
ation, impaired apoptosis, loss of differentiation, immortal-
ization, neovascularization, invasion, and metastatic spread
(Hanahan and Weinberg 2000). This evolutionary trans-
formation can be operationally divided into distinct stages,
including initiation, promotion, progression, and metastasis
(DiGiovanni 1992). Mutations in both oncogenes and tumor
suppressor genes are found in end-stage tumors, implying
their causal role in tumor development. However, the
association of mutations in speciﬁc genes with speciﬁc
phenotypic states during tumor progression is poorly
characterized for most human solid tumors. It is also largely
unknown whether each mutation is an independent event or
whether there is a preferred sequence or combination of
mutations that is favored. The purpose of this study is to
investigate the functional interactions between the muta-
tional activation of the oncogene Ras, and two tumor
suppressors, p19
Arf, and p53, using a multistage epithelial
tumor model.
Ras is among the most frequently mutated oncogenes in
human cancer, with approximately 30% of tumors carrying
an activating mutation in one of three family members, Hras,
Kras, or Nras (Bos 1989). Cancer-associated mutations in Ras
result in constitutively active Ras protein. Ras is a nodal
signaling molecule that regulates multiple signaling pathways,
leading to profound changes in cellular proliferation,
apoptosis, differentiation, senescence, cytoskeletal organiza-
tion, adhesion, and migration (Campbell et al. 1998). Ras has
also been shown to induce invasiveness and metastasis of
cancer cells (Pozzatti et al. 1986; Webb et al. 1998; Varghese et
al. 2002). These pleiotropic effects suggest Ras may inﬂuence
multiple steps in tumor progression.
p53 is the most frequently mutated tumor suppressor gene
in human cancer, with more than 50% of tumors showing
mutations (Hollstein et al. 1994). p53 is a nodal signaling
protein that coordinates the cellular response to different
types of stress, including oncogene activation, DNA damage,
abnormal cell adhesion, altered ribonucleotide pools, hyp-
oxia, and redox stress (Ko and Prives 1996; Giaccia and
Kastan 1998). These stress stimuli are thought to activate p53
by inducing posttranslational modiﬁcations that stabilize p53
and enhance its ability to act as a transcription factor
(Siognov and Haupt 1999; Vousden and Lu 2002). Loss of p53
function leads to loss of cell cycle checkpoints, impaired
apoptosis, genomic instability, and tumor progression. How-
ever, a major unresolved issue is, of the many signals that have
been shown to activate p53 using a variety of model systems,
which one regulates p53 during autochthonous tumor
progression.
A mechanistic connection between Ras signaling and
activation of p53 that involves the tumor suppressor p19
Arf
was recently established. p19
Arf (p14
Arf in humans; Stott et al.
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Ink4a/p19
Arf locus, but because it is
transcribed in an alternative reading frame, the protein
product is unrelated to the p16
Ink4a protein (Quelle et al.
1995; Kamijo et al. 1997). Deletions or mutations at the
p16
Ink4a/p19
Arf locus are frequently (more than 50% of cases)
seen in human tumors (Ruas and Peters 1998). p19
Arf was
established as a bona ﬁde tumor suppressor in studies
showing that mice lacking p19
Arf are highly susceptible to
spontaneous tumorigenesis (Kamijo et al. 1997). In vitro
studies had shown that enforced expression of oncogenes
such as Ras, c-Myc, and E1A activated p53 and induced growth
arrest, senescence, or apoptosis depending on the cell type or
oncogene used (Lowe and Ruley 1993; Hermeking and Eick
1994; Serrano et al. 1997). These cellular responses were
impaired in cells lacking p53, indicating that functional p53
was required. The involvement of p19
Arf was ﬁrst suggested
by experiments showing that enforced expression of Ras,
Myc, and E1A in cells induced p19
Arf, leading to G1 and G2
cell cycle arrest that was p53-dependent (Kamijo et al. 1997;
Stott et al. 1998). Cells lacking p19
Arf showed impaired p53
induction in response to these oncogenes, and, like p53-
deﬁcient cells, escaped growth arrest and were immortalized
(Zindy et al. 1998; de Stanchina et al. 1998; Palmero et al.
1998; Lin and Lowe 2001; Ferbeyre et al. 2002). In vivo
evidence linking oncogene signaling to p19
Arf and p53 was
obtained in a lymphoma model. B-cell lymphomas from
transgenic El-myc mice also show a dependence on p19
Arf to
activate p53, and El-myc mice lacking either p19
Arf or p53
developed lymphomas much faster (Eischen et al. 1999;
Schmitt et al. 1999). p19
Arf regulates p53 through mutual
binding to the p53 regulator Mdm2. The levels of p53 in cells
are normally kept low because of feedback regulation by the
Mdm2 protein (Haupt et al. 1997; Kubbutat et al. 1997).
Mdm2 binds to p53 and targets it for degradation by nuclear
to cytoplasmic shuttling and through the E3 ubiquitin ligase
activity of Mdm2 (Roth et al. 1998; Honda and Yasuda 1999).
p19
Arf sequesters Mdm2 from p53 and inhibits the ubiquitin
ligase activity of Mdm2, resulting in increased stability and
accumulation of p53 (Pomerantz et al. 1998; Tao and Levine
1999; Weber et al. 1999; Zhang and Xiong 1999).
The importance of the Ras-p19
Arf-p53 pathway in growth
arrest was established in culture systems involving the
ectopic overexpression of mutant Ras in both murine
embryonic ﬁbroblasts (Ferbeyre et al. 2002; Palmero et al.
1998) and primary epidermal keratinocytes (Lin and Lowe
2001). Both in vitro and in vivo models have established that
the gene dosage of mutant Ras is critical for its oncogenic
function. A single copy of mutant Ras is insufﬁcient to
transform cells; at least two mutant alleles are required
(Finney and Bishop 1993). Duplication or even ampliﬁcation
of mutant Ras alleles is frequently observed in tumors
(Quintanilla et al. 1986; Bremner and Balmain 1990). Ras
activates multiple signaling pathways, and quantitative
differences in Ras activity can lead to activation of different
signals and qualitatively different cellular phenotypes
(Shields et al. 2000). Cell culture conditions can add
additional stress signals that are known to impinge on
p19
Arf and p53, leading to cell cycle arrest (Sherr and
DePinho 2000; Lowe and Sherr 2003), and cannot recapit-
ulate the complex cellular ecology of tumor progression.
Thus, to understand the interactions between Ras, p19
Arf,
and p53 that drive tumor progression, an autochthonous
tumor model is required. Since more than 90% of human
cancers are epithelial in origin, a carcinoma model system is
favored.
Mouse skin carcinogenesis is perhaps the best-character-
ized in vivo model of epithelial neoplasia and was instru-
mental in establishing the concepts of initiation, promotion,
and progression (DiGiovanni 1992). The two-stage chemical
protocol involves treatment of mice with a carcinogen,
DMBA, followed by multiple applications of TPA. This
treatment induces benign squamous cell papillomas, nearly
100% of which have sustained an AT mutation in codon 61
of Hras (Quintanilla et al. 1986). As this mutation results in
constitutively active Ras protein, this protocol is ideal to
study the biological consequence of Ras activation during
the entire natural history of tumor progression. Papillomas
consist of a series of folded epidermal or follicular hyper-
plasias that protrude from the skin surface. Papillomas have
dysplastic characteristics including disturbed cell polarity,
basal cell hyperplasia, disturbed maturational sequence,
increased mitotic activity, and increased nuclear to cyto-
plasmic ratio (Yuspa 1994). In most strains of mice,
progression of these benign papillomas to malignant
squamous cell carcinomas (SCCs) is a rare and late event.
SCCs are usually endophytic tumors that present as plaques
with an ulcerated surface. These tumors break through the
basement membrane and progressively invade the under-
lying dermis and subcutaneous tissues, and rarely, can
metastasize to regional and distant sites. SCCs are charac-
terized by a disorderly proliferation of epithelial cells with
increased cellular atypia and abnormal mitotic ﬁgures, and
are classiﬁed into four grades: well-differentiated, moder-
ately differentiated, poorly differentiated, and spindle cell
carcinoma. The unique advantage of this skin tumor model is
the ability to directly observe and quantify these evolu-
tionary stages.
Loss of p53 function is strongly associated with the benign
to malignant transition of chemically induced SCCs. Muta-
tions in p53 are seen more frequently in carcinomas than in
papillomas (Burns et al. 1991; Ruggeri et al. 1991). p53
knockout mice show accelerated malignant progression of
SCCs (Kemp et al. 1993). The strongest association of p53
with malignant progression was revealed in p53
þ/  mice, in
which loss of the remaining wild-type allele of p53 was seen
in carcinomas but not papillomas, indicating a strong
selective pressure to completely inactivate p53 during this
transition. Accelerated malignant progression seen in the
absence of p53 was accompanied by extensive loss of
differentiation and lymph node metastasis, indicating that
p53 inhibits multiple steps involved in malignant tumor
progression.
Here, we used the mouse skin tumor model to examine the
role of p19
Arf in regulating the levels and tumor suppressor
activity of p53. In addition, we addressed the biological and
functional signiﬁcance of alterations in p19
Arf, p53, or both
during tumor initiation, promotion, progression, and meta-
stasis. Similar to p53-null mice, loss of p19
Arf resulted in
increased malignant conversion, more aggressive tumors, and
frequent and rapid metastasis. However, in contrast to p53-
null mice, p19
Arf-null mice had greater tumor numbers and
tumor growth rates, indicating additional, p53-independent
tumor suppressor functions for p19
Arf.
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p19
Arf and Tumor ProgressionResults
Increased Papilloma Number and Size in p19
Arf-Deficient
Mice
Both in vitro and in vivo studies have demonstrated that
p19
Arf is a tumor suppressor (Eischen et al. 1999; Kamijo et al.
1999; Schmitt et al. 1999; Lin and Lowe 2001). However, other
than regulation of p53, little else is known about the role of
p19
Arf in tumor suppression. To address this, groups of
p19
Arfþ/þ, p19
Arfþ/ , and p19
Arf /  littermates were treated with
a single dose of DMBA followed by twice weekly application
of TPA for 15 wk (see Materials and Methods). Papillomas
b e g a nt oa p p e a ri na l lt h r e eg e n o t y p e sa f t e r9w ko f
promotion. By 20 wk, p19
Arfþ/  and p19
Arf /  mice showed a
signiﬁcant increase in papilloma number and size compared
to wild-type mice (Figure 1A). Relative to wild-type litter-
mates, p19
Arf /  mice had an average of 2.97 more papillomas
(95% CI (0.70, 5.24); p = 0.010) and p19
Arfþ/  mice had an
average of 2.60 more papillomas (95% CI (0.05, 5.14); p =
0.045) in weeks 18–30 after DMBA administration. Average
papilloma size was also greater in both p19
Arf /  and p19
Arfþ/ 
mice compared to wild-type mice (Figure 1B). This effect was
seen as early as 12 wk and increased through time so that by
28 wk, 33% (47/141) of papillomas from p19
Arf /  mice were
greater than 8 mm in diameter versus 14% (38/267) from
wild-type mice (p , 0.0001). Papillomas from p19
Arf-deﬁcient
mice measured up to 16 mm in diameter while very few
papillomas on wild-type mice measured more than 9 mm.
Thus, p19
Arf deﬁciency resulted in faster growing papillomas,
indicating a role for p19
Arf in regulating the early stages of
benign tumor growth.
Mutations in Hras are found in more than 95% of DMBA/
TPA-induced skin tumors (Quintanilla et al. 1986; Kemp et al.
1993). In vitro studies showed that mutant Ras induces p19
Arf,
which, in turn, inhibits Ras-induced proliferation (Sherr and
Weber 2000). Thus, loss of p19
Arf might reduce or eliminate
the need to mutate Ras. All papillomas from p19
Arfþ/þ (5/5),
p19
Arfþ/  (4/4), and p19
Arf /  (5/5) mice contained the identical
AT transversion at codon 61 of Hras, resulting in an amino
acid change from glutamine to leucine and a constitutively
activated Ras protein (Quintanilla et al. 1986). Thus, mutation
of Ras is very strongly selected for during epithelial carcino-
genesis, with or without the presence of p19
Arf, and loss of
p19
Arf cooperates with activated Ras to accelerate tumor
growth.
Increased Malignant Progression and Metastasis in
p19
Arf-Deficient Mice
The rate of malignant conversion of papillomas to
carcinomas is greatly increased in the absence of p53
function (Kemp et al. 1993). To determine if loss of p19
Arf
had a similar effect, progression was quantiﬁed by visual
inspection and conﬁrmed by histologic analysis. The rate of
conversion from papillomas to carcinomas was dramatically
accelerated in p19
Arf-deﬁcient mice. Carcinomas developed
in p19
Arf /  mice as early as 14 wk after initiation, whereas
papillomas from p19
Arfþ/þ mice began to convert much later,
after 22 wk (Figure 1C). By 28 wk, 100% of the p19
Arf /  mice
Figure 1. Skin Tumor Multiplicity, Size, and
Progression in p19
Arf-Deficient Mice
(A) Average number of papillomas (more
than 2 mm in diameter) per mouse is
plotted versus the number of weeks
postinitiation. Both p19
Arf (Arf)
þ/  and
p19
Arf /  mice show greater numbers of
tumors than p19
Arfþ/þ mice.
(B) Comparison of papilloma size (in
mm) between p19
Arfþ/þ,p 1 9
Arfþ/ , and
p19
Arf /  mice through 28 wk postinitia-
tion. An increase in the largest size class
oftumorsis seen in p19
Arfþ/ andp19
Arf / 
mice but not p19
Arfþ/þ mice.
(C) Percentage of mice bearing at least
one carcinoma is plotted versus the
number of weeks postinitiation.p19
Arf / 
mice show the shortest latency and
greatest incidence of carcinoma conver-
sion, with p19
Arfþ/  mice showing an
incidence between the p19
Arf /  and
p19
Arfþ/þ mice. Time of appearance of
lymph node metastasis is noted above
the graph as a vertical line for each
mouse analyzed. Metastasis to lymph
node occurred frequently and sooner
in p19
Arf-deﬁcient mice than in wild-
type mice.
DOI: 10.1371/journal.pbio.0020242.g001
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p19
Arf and Tumor Progressionhad at least one carcinoma, compared to only 25% of the
wild-type mice. The p19
Arfþ/  mice showed an intermediate
conversion rate, with 60% of the mice bearing at least one
carcinoma, indicating an p19
Arf gene dosage effect on
malignant progression. In addition to reducing the latency,
p19
Arf deﬁciency increased the frequency of malignant
conversion. The odds of developing a carcinoma within 30
wk after DMBA administration was 8.10 times higher for
p19
Arf / mice (95% CI (1.90, 34.56); p = 0.005) and 3.11 times
higher for p19
Arfþ/  mice (95% CI (0.90, 10.77); p = 0.073)
compared to wild-type mice. The reduced carcinoma latency
and increased conversion frequency in the p19
Arf-null mice
implicate loss of p19
Arf as a critical rate-limiting step in
malignant SCC progression.
Histologic analysis revealed that the carcinomas from
control mice ranged in grade from well-differentiated to
poorly differentiated SCCs. Carcinomas from p19
Arfþ/  and
p19
Arf /  mice also showed a range of grades but a signiﬁcant
number (9/12) were characterized as spindle cell carcinomas.
These were characterized by packed and spindle-shaped cells
with elongated pleiomorphic nuclei and abundant abnormal
mitotic ﬁgures. These cells grew in a homogenous pattern
with very little evidence of the cellular organization typical of
low-grade tumors. These tumors showed focal areas of
squamous differentiation, indicating that they were derived
from squamous epithelium.
p19
Arf deﬁciency also increased dissemination and estab-
lishment of metastatic SCCs. Carcinoma-bearing p19
Arf-
deﬁcient mice frequently presented with enlarged lymph
nodes, and in several cases tumors were noted on the lungs.
(Table 1; Figure 2). Histologic analysis revealed that these
lymph nodes and lung tumors contained cells with features
similar to the primary SCCs, including squamous differ-
entiation, keratin pearls, high mitotic index, nuclear pleo-
morphism, and disturbed cell polarity (Figure 2D and 2E).
Immunostaining with a keratin-speciﬁc antibody showed that
these cells were epithelial in origin, conﬁrming that they were
metastatic SCCs (Figure 2F and 2G). 60% of local enlarged
lymph nodes from carcinoma-bearing p19
Arf /  mice con-
tained such squamous carcinoma deposits, compared to 10%
of those from wild-type mice (Table 1). Metastatic lesions
from p19
Arf-deﬁcient mice were seen as early as 16 wk after
initiation and must have occurred very soon after or
simultaneously with papilloma to carcinoma conversion (see
top of Figure 1C). In contrast, only one metastatic lesion was
seen in one p19
Arfþ/þ mice through 36 wk of observation.
p19
Arfþ/  mice displayed an intermediate frequency of meta-
stasis. Newly formed blood vessels, some measuring up to 2
mm in diameter, were seen on the underside of each tumor
and appeared to lead directly to the inguinal or brachial
lymph node (Figure 2A and 2B). Several primary p19
Arf-
deﬁcient carcinomas showed clear evidence of penetration of
tumor cells through blood vessel walls, with intravascular rafts
of tumor cells seen (Figure 2C), indicating a route by which
tumor cells could migrate to distant organs through the
circulation. Thus, in addition to increasing benign tumor
growth, loss of p19
Arf accelerated both benign to malignant
conversion and metastatic spread of epithelial tumors.
Tumors lacking p19
Arf have a higher potential for metastatic
spread.
Reduced p53 Expression in Papillomas from
p19
Arf-Deficient Mice
The p53 expression in DMBA/TPA-induced papillomas is
increased relative to adjacent normal skin (Kemp et al. 2001).
Table 1. Metastatic Frequency of SCC
Genotype Lymph Node Lung
p19
Arfþ/þ 1/10 0/10
p19
Arfþ/  4/10 2/10
p19
Arf /  6/10 4/10
Denominator indicates number of tissues examined. Numerator indicates number
of tissues bearing SCC.
DOI: 10.1371/journal.pbio.0020242.t001
Figure 2. Metastasis of Primary SCC to Lymph Nodes and Lungs in
p19
Arf-Deficient Mice
(A) Underside of skin from tumor-bearing mouse shows newly formed
blood vessels surrounding tumor site (arrow) and leading to inguinal
lymph node (arrowhead).
(B) Enlarged inquinal lymph node (left) containing metastatic SCC
and blood vessel formation (arrow) compared to normal lymph node
(right).
(C) H&E stain of carcinoma section with prominent blood vessel (bv).
Carcinoma cells (ca) have penetrated blood vessel wall (arrow).
(D) H&E stain of lymph node bearing inﬁltrating SCC cells (arrow)
among normal lymphocytes (arrowhead).
(E) H&E stain of lymph node bearing metastatic differentiated SCC.
(F) Immunostain with pan-keratin antibody of papilloma.
(G) Immunostain with pan-keratin antibody of lymph node with
metastatic SCC.
(H and I) H&E stain of normal lung (arrowhead) with large metastatic
SCC deposit (arrow).
(J) H&E stain of lung metastasis with secondary site of inﬁltration
(arrow).
(D–G, J): 203 magniﬁcation. Inserts in (E–G): 403 magniﬁcation.
DOI: 10.1371/journal.pbio.0020242.g002
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p19
Arf and Tumor ProgressionAs multiple signals can lead to the accumulation of p53,
including activated oncogenes, DNA damage, and hypoxia, it
was not clear which was operative in this setting. As nearly all
carcinogen-induced papillomas carry mutations in Hras, we
questioned whether increased p53 expression was due to
signaling from Ras through p19
Arf. Western blot analysis of
nuclear lysates showed increased levels of both p19
Arf and
p53 in wild-type papillomas compared to normal skin
(Figures 3 and 4). In contrast, p53 expression was not
detectable in papillomas from p19
Arf /  mice and was
intermediate and variable in papillomas from p19
Arfþ/  mice.
Immunostaining of parafﬁn-embedded sections conﬁrmed
the Western analysis, with nuclear staining of p53 detected in
the epidermal cells of papillomas from wild-type mice,
reduced numbers of p53-positive cells in the p19
Arf hetero-
zygous papillomas, and undetectable p53 staining in p19
Arf-
null papillomas (Figure 3B). To determine if p53 could still be
induced in the absence of p19
Arf by an alternative pathway,
tumor-bearing mice were irradiated with 4Gy ionizing
radiation and sacriﬁced 4 h later, and their tissues were
examined for p53 expression. Both Western blot analysis and
immunostaining revealed prominent induction of p53 in
basal cells of normal skin and papillomas from both wild-type
and p19
Arf-null mice (Figure 3A and 3B). Thus, the induction
of p53 seen in mutant Ras-containing tumors is due to
signaling through p19
Arf. These results provide in vivo
conﬁrmation of the model, largely derived from in vitro
studies, that posits that signaling from mutant Ras acts
through p19
Arf to induce p53. Other pathways to activate p53,
such as those initiated by DNA damage, remain functional in
the absence of p19
Arf.
Loss of the Wild-Type p19
Arf Allele in Tumors from
p19
Arfþ/  Mice Occurs During Benign to Malignant
Conversion
p19
Arfþ/  mice displayed an intermediate rate of papilloma
to carcinoma conversion (see Figure 1C). Two genetic models
could explain this heterozygous phenotype. p19
Arf could be
haploinsufﬁcient, in which case no mutation or loss of
heterozygosity (LOH) should be seen in the remaining wild-
type p19
Arf allele in carcinomas. Alternatively, p19
Arf could be
recessive, in which case LOH or reduction to a homozygous
null state would be expected. The fate of the wild-type allele
of p19
Arf in tumors from heterozygous mice was assessed by
semiquantitative PCR analysis of genomic DNA. Three of 15
(20%) papillomas examined showed evidence of loss of the
wild-type p19
Arf allele, compared to ten of 15 (67%)
carcinomas (p = 0.0027) (Figure 4A), indicating LOH occurs
primarily during malignant conversion. We next examined
p19
Arf expression in tumor lysates by Western blot analysis
with a p19
Arf-speciﬁc antibody. In wild-type mice, p19
Arf
protein was elevated in all papillomas and three of six
carcinomas compared to normal skin (Figure 4B). Increased
expression of p19
Arf is consistent with activation of Ras in
these tumors. p19
Arf expression was also increased in
papillomas from p19
Arfþ/  mice but not to the levels seen in
Figure 3. Reduced p53 Expression in Skin Tumors from p19
Arf-Deficient
Mice
(A) Western blot analysis of nuclear lysates from skin tumors from
p19
Arf (Arf)
þ/þ, p19
Arfþ/ , and p19
Arf /  mice using p53-speciﬁc anti-
body. PA, papilloma; skin IR, irradiated normal skin
(B) p53 immunostain of parafﬁn-embedded skin tumor sections from
p19
Arfþ/þ, p19
Arfþ/ , and p19
Arf / mice (arrows indicate positive stained
cells) (top). p53 immunostain of irradiated papillomas (IR) from
p19
Arfþ/þ and p19
Arf /  mice (bottom). p53 is not detected in normal
skin or tumors from p19
Arf /  mice, but is induced by irradiation in
both normal and tumor cells from p19
Arf /  mice.
DOI: 10.1371/journal.pbio.0020242.g003
Figure 4. LOH of Wild-Type p19
Arf Allele in p19
Arfþ/  Tumors
(A) LOH analysis by semiquantitative PCR of the wild-type p19
Arf
allele in p19
Arfþ/  papillomas and carcinomas. Gradient made from
kidney DNA used for quantitation of wt/mu ratio (top row). wt, wild-
type allele; mu, knockout allele; asterisk, loss or reduction of p19
Arf
wild-type band.
(B) Western blot analysis of nuclear lysates from papillomas (PA) and
carcinomas (CA) from p19
Arfþ/þ, p19
Arfþ/ , and p19
Arf /  mice.
DOI: 10.1371/journal.pbio.0020242.g004
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p19
Arf and Tumor Progressionwild-type mice, indicating that p19
Arf protein levels in tumors
reﬂect p19
Arf gene dosage. p19
Arf protein was reduced or
undetectable in four of six carcinomas from p19
Arfþ/  mice,
consistent with the LOH data. Collectively, these data
indicate that p19
Arf expression is induced in tumors. Germ-
line deletion of one p19
Arf allele provides a selective
advantage during early tumor growth, and loss of the second
allele confers an additional phenotype, destabilization of p53,
and enhanced malignant progression.
Independent Contributions of p19
Arf and p53 to
Tumorigenesis
The observations that p19
Arf and p53 were upregulated in
papillomas, that p53 expression was reduced in p19
Arf-null
papillomas, and that loss of p19
Arf had a similar effect on
tumor progression as that of loss of p53, provide strong in
vivo support of the model whereby p19
Arf regulates p53 in
response to mutational activation of Hras. However, en-
hanced tumor growth in p19
Arf-null mice, in contrast to
reduced tumor growth in p53-null mice (Kemp et al. 1993),
suggests additional tumor suppressor functions of p19
Arf,
independent of p53. To examine the effect of the combined
loss of p53 and p19
Arf tumor suppressors, skin tumors were
induced in p19
Arf and p53 single and compound mutant
littermates. Relative to wild-type mice, p53-null mice devel-
oped fewer tumors, averaging 4.05 fewer papillomas (95% CI
( 6.10,  2.00); p = 0.0001) 10–16 wk after the DMBA
administration, while p19
Arf-null mice averaged 2.68 more
papillomas (95% CI (0.52, 4.84); p = 0.015) 18–40 wk after the
DMBA administration (Figure 5A). The p19
Arf /p53 double-
null mice showed a papilloma multiplicity similar to wild-type
mice. p53
 / tumors were also smaller, while both p19
Arf / and
p19
Arf / p53
 /  tumors were larger compared to wild-type
tumors. p19
Arf and p53 also affected tumor size and
morphology. Wild-type papillomas were highly exophytic,
while tumors from both p19
Arf- and p53-deﬁcient mice grew
in a ﬂatter, endophytic pattern (Figure 5B). Thus, loss of
p19
Arf increased the number and size of both wild-type p53
and p53-null tumors, demonstrating that p53 and p19
Arf
contribute independently to the early stages of tumor
development.
To determine whether tumor growth in mice lacking p19
Arf
or p53 is due to altered proliferation, additional cohorts of
mice were treated with DMBA/TPA. Tumor-bearing mice 8–
10 wk post DMBA treatment were injected with BrdU and
sacriﬁced 1 h later. p53-null papillomas showed a reduced
BrdU labeling index compared to wild-type mice, while the
p19
Arf-null tumors showed a higher BrdU labeling index
(Figure 5C). The p19
Arf /p53 double-null papillomas showed a
proliferative index similar to that of wild-type tumors. Thus,
decreased proliferation contributes to the reduced tumor
growth seen in the p53-null mice. Apoptotic cells were very
rare in papillomas regardless of p53 genotype or radiation
exposure (apoptotic index over 40-fold less than proliferation
index) (unpublished data). Thus, p53-regulated apoptosis
does not appear to play a major role in SCC development, at
least at the papilloma stage.
Tumor Progression in p19
Arf /p53 Compound Mutant Mice
To determine if p19
Arf and p53 cooperate during tumor
progression, papilloma to carcinoma conversion was eval-
uated in p19
Arf / ,p 5 3
 / , and p19
Arf / p53
 /  littermates.
Tumor progression was accelerated in all p19
Arf- and p53-
deﬁcient genotypes compared to wild-type littermates (Figure
6A). Carcinoma latency and multiplicity was almost identical
for p19
Arf / mice regardless of p53 genotype (p53
þ/þ, p53
þ/ , or
Figure 5. Tumor Multiplicity and Proliferative Index in p19
Arf /p53
Compound Mutant Mice
(A) Average number of papillomas (more than 2 mm in diameter) per
mouse is plotted against the number of weeks post-initiation.
(B) Image of wild-type, p19
Arf (Arf)
 / , p53
 / , and p19
Arf / p53
 /  mice
with skin tumors at time of sacriﬁce. Wild-type mice show large
exophytic tumors, while both p19
Arf- and p53-deﬁcient mice have
endophytic tumors. Note larger tumors in p19
Arf /p53 compound
mutant mice relative to p53 single mutants.
(C) BrdU-positive cells in papillomas from wild-type, p53
 / , p19
Arf / ,
and p19
Arf / p53
 /  mice at 10 wk postinitiation. (Bars represent
average counts 6 standard deviation from ten ﬁelds and ﬁve mice).
p53
 /  tumors show signiﬁcantly fewer BrdU-positive cells than either
p19
Arf /  or wild-type tumors (p , 0.05, Wilcoxon one-sided t-test).
DOI: 10.1371/journal.pbio.0020242.g005
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 / ) (Figure 6A), indicating no cooperation between p19
Arf
and p53 for malignant conversion per se. However, the size of
carcinomas in both p19
Arf /  and p19
Arf / p53
 /  mice was
considerably greater than that seen in p53
 /  mice at
comparable time points (see Figure 5B). This conﬁrms a
signiﬁcant impact of p19
Arf on suppressing tumor growth
that does not require p53.
In p53
þ/  mice there is strong selective pressure to lose the
wild-type allele during conversion to malignancy (Kemp et al.
1993). As p19
Arf regulates p53, we next wished to determine if
the selective pressure to lose p53 was reduced in the absence
of p19
Arf. Tumors from p53
þ/  mice of all three p19
Arf
genotypes ( p19
Arfþ/þ, p19
Arfþ/ , and p19
Arf / ) were assessed for
LOH of p53 by semiquantitative PCR analysis of genomic
DNA. Two out of seven papillomas from p19
Arfþ/þp53
þ/  mice
show loss of the remaining p53 allele, while all papillomas
examined from p19
Arfþ/ p53
þ/  (n = 8) and p19
Arf / p53
þ/  (n
= 8) mice show retention of wild-type p53 (Figure 6B). Seven
of 14 (50%) carcinomas from p19
Arfþ/þp53
þ/ , and three of 14
(21%) from p19
Arfþ/ p53
þ/ , but only one of 12 (8%) from
p19
Arf / p53
þ/  (p = 0.036) showed loss of p53. Thus, deletion
of p19
Arf disrupts the activation of p53 and thereby reduces
selection for mutations in p53 during malignant progression.
Discussion
Using a multistage model of tumor progression, we have
examined the functional interactions between the oncogene
Hras and the tumor suppressors p19
Arf and p53. Somatic
mutation of Ras is an early and frequent event in this model
of tumor development. Against this backdrop, p19
Arf has at
least two distinct tumor suppressor properties, which act at
different stages of tumor development and which show a
range of gene dosage effects. Loss of one or both p19
Arf alleles
leads to accelerated growth of benign tumors, indicating
p19
Arf is partially haploinsufﬁcient for suppression of this
early growth phenotype. Although p19
Arf regulates p53 at this
stage, suppression of tumor growth per se by p19
Arf does not
appear to be mediated through p53. p19
Arf also inhibits the
benign to malignant transition and subsequent tumor cell
dissemination and metastasis, and this effect of p19
Arf is, in
contrast, mediated through p53. LOH of p19
Arf occurs
preferentially in malignant tumors, indicating complete loss
of p19
Arf is favored during progression. Thus, p19
Arf inhibits
several stages in Ras-driven tumor progression. Furthermore,
Ras is connected to both p19
Arfand p53 through a signaling
pathway, indicating that selection for mutations in the p19
Arf /
p53 pathway are a direct consequence of the initial Ras
mutation.
Ras, p19
Arf, p53, and Early Tumor Growth
The observation that Hras mutations are found at high
frequency in papillomas from wild-type and both p19
Arf- and
p53-deﬁcient mice indicates that squamous epithelial cells
harboring Hras mutations have a strong selective advantage,
with or without the presence of p19
Arf or p53. This permits
analysis of the effects of Ras on deﬁned genetic backgrounds
in the natural setting of tumor cell evolution. The expression
levels of both p19
Arf and p53 were increased in wild-type
papillomas but not in p19
Arf /  papillomas, indicating that
p19
Arf regulates p53 in response to activated Ras in vivo.
However, other signals to induce p53, such as those stemming
from DNA damage, remain intact in the absence of p19
Arf,a s
shown by the rapid increase in p53 in irradiated p19
Arf-null
tumors. Thus, of the many stimuli that have been shown to
activate p53 using a variety of experimental systems (Ko and
Prives 1996; Giaccia and Kastan 1998), the Ras-p19
Arf pathway
appears to be the major signal that operates during SCC
development. This indicates that p53 activation is an intrinsic
consequence of the oncogenic pathway that drives tumor
growth, and is not due to other microenvironmental factors
(e.g., those induced by hypoxia or due to lack of survival
factors) or exogenous stimuli (e.g., DNA damage inducers).
However, it remains possible that these other modes of p53
activation might predominate in other tumor types or in
other circumstances.
Despite the fact that both p19
Arf and p53 were induced in
papillomas, loss of p19
Arf or p53 had opposite effects on early
Figure 6. Tumor Progression and p53 LOH in p19
Arf /p53 Compound
Mutant Mice
(A) Average number of carcinomas per mouse is plotted against the
number of weeks postinitiation. Tumor progression was accelerated
in all p19
Arf (Arf)- and p53-deﬁcient genotypes compared to wild-type
littermates. Carcinoma latency and multiplicity was almost identical
for p19
Arf / mice regardless of p53 genotype (p53
þ/þ, p53
þ/ , or p53
 / ).
(B) LOH of the wild-type p53 allele by semiquantitative PCR in p19
Arf
/p53 compound tumors. Gradient made from kidney DNA used for
quantitation of wt/mu ratio (top row). wt, wild-type allele; mu,
knockout allele; asterisk, tumors with reduction of wild-type p53.
DOI: 10.1371/journal.pbio.0020242.g006
PLoS Biology | www.plosbiology.org August 2004 | Volume 2 | Issue 8 | e242 1144
p19
Arf and Tumor Progressiontumor growth. p19
Arf deﬁciency resulted in increased tumor
cell proliferation and tumor growth while p53-deﬁcient mice
had reduced tumor cell proliferation, tumor numbers, and
tumor size. The observation that tumors harboring mutant
Ras grew faster in the presence of p53 than in the absence of
p53 differs from in vitro studies, in which ectopically
expressed Ras induces p53-dependent growth arrest or
senescence (Palmero et al. 1998; Zindy et al. 1998; Lin and
Lowe 2001). These different outcomes are likely due to
different experimental conditions. Ex vivo culture per se
induces stress, which can further induce p53 and accelerate
senescence (Lowe and Ruley 1993; Serrano et al. 1997; Sherr
and DePinho 2000). Moreover, the levels of active Ras protein
likely differ; our autochthonous tumor model begins with a
single cell that has undergone a mutation at the endogenous
Hras locus, and subsequent tumor growth occurs in the
context of surrounding normal cells. Locally produced growth
factors or TPA treatment may attenuate the effect of Ras on
p53, effectively dampening the response. Thus, the absolute
levels of both Ras and p53, as well as cell type involved and the
local cellular ecology, may dictate the outcome.
Greenhalgh al. (1996) also reported reduction in Ras-
transgene-induced skin tumors in a p53-null background. We
suggest that the acute effect of a constitutively active
oncogene driving cellular proliferation, combined with lack
of cell cycle checkpoints due to p53 deﬁciency, may generate
excessive genetic instability, which may initially impair
overall cellular ﬁtness. This may be especially true at the
early post-initiation stage where a small number of incipient
tumor cells are competing with surrounding normal cells.
This idea is consistent with the longstanding observation that
p53-deﬁcient mice (Donehower et al. 1992), and Li-Fraumeni
patients who carry a germline p53 mutation (Vogelstein
1990), rarely develop multiple tumors, which would be
expected if loss of p53 provided an early selective advantage.
Also, in many human malignancies, mutations in p53 are
infrequent in early premalignant lesions and much more
common in late-stage disease, indicating a long latency
between oncogene activation and loss of p53. Further genetic
or epigenetic changes may be required for a cell to adapt to
the combined effect of a dominant oncogene and loss of p53
to gain a ﬁtness advantage. Loss of p19
Arf appears to be one
such change, as reduced tumor growth due to the absence of
p53 was rescued by loss of p19
Arf.
Although p19
Arf regulates p53, suppression of tumor
growth per se by p19
Arf does not appear to be mediated
through p53. Other reports have suggested that p19
Arf has
tumor suppressor functions that are independent of p53.
p19
Arf-null mice show a broader spectrum of spontaneous
tumors compared to p53-null mice (Donehower et al. 1992;
Kamijo et al. 1999). Mice lacking both p19
Arf and p53 showed
a wider range of tumor types than animals lacking either gene
alone, and many developed multiple primary tumors (Weber
e ta l .2 0 0 0 ;M o o r ee ta l .2 0 0 3 ) .P r e m a l i g n a n tB - c e l l s
expressing oncogenic El-myc and lacking both p19
Arf and
p53 proliferated at a faster rate than cells lacking either p19
Arf
or p53 alone (Weber et al. 2000). Indeed, both p19
Arf and p53
are lost in a wide spectrum of human cancers, both familial
and sporadic, at very high frequency (Ruas and Peters 1998;
Vonlanthen et al. 1998). Microarray and GeneChip analysis of
genes induced by a conditionally regulated p19
Arf has
identiﬁed members of the B-cell translocation gene family
whose induction is independent of p53 (Kuo et al. 2003).
Expression of these genes inhibits cell proliferation and
induces cell cycle arrest. p19
Arf can colocalize with the human
replication protein A, suggesting a direct role for p19
Arfin
DNA synthesis (Yarbrough et al. 2002). p19
Arf has also been
shown to inhibit ribosomal RNA processing (Sugimoto et al.
2003) and to repress NF-jB transactivation (Rocha et al.
2003). Finally, p19
Arf regulates vascular regression independ-
ent of p53, suggesting a role for p19
Arf in angiogenesis.
(McKeller et al. 2002). The functional relevance of these
phenotypes for tumor suppression by p19
Arf remains to be
elucidated.
Ras, p19
Arf, p53, and Malignant Progression
In the DMBA/TPA model, conversion of papillomas to
carcinomas is a relatively rare event and can take up to 6–12
mo. Phenotypes associated with conversion include loss of
basement membrane integrity, invasion of epithelial tumor
cells into the dermis, loss of differentiation, and increased
cellular atypia. Even more rarely, these carcinoma cells can
metastasize, which involves additional phenotypic changes
including, extravasation, migration, attachment, and estab-
lishment of tumor growth in an ectopic tissue. Although
benign tumor growth differed between p19
Arf- and p53-
deﬁcient mice, both mutant mice showed dramatically
accelerated progression to malignancy and rapid metastasis.
Thus, benign tumors lacking either p19
Arf or p53 are at high
risk for metastasis. In p19
Arf-deﬁcient mice, progression was
similar with or without the presence of p53 and did not
involve p53 LOH, indicating that loss of p19
Arf decreased
selection for p53 mutations during progression and that
p19
Arf acts through p53 at this stage. Schmitt et al. (1999) also
reported increased lymphoma dissemination in El-myc p53
 / 
mice relative to El-myc mice alone. From a clinical
perspective, then, the most relevant effect of the p19
Arf-p53
pathway may be to inhibit malignant conversion and metas-
tasis. Loss of p19
Arf and/or p53 can increase progression and
metastasis by several mechanisms. Deﬁciency in p19
Arf or p53
could indirectly affect progression via increased genetic
instability, increased generation of mutants, and accelerated
tumor evolution. This view postulates the existence of a
distinct class of genes whose dysfunction increases progres-
sion and metastasis. It also requires a series of clonal
evolutionary steps to select for cells carrying mutations in
these genes. Alternatively, loss of p19
Arf or p53 can directly
affect cellular phenotypes associated with progression
through transcriptional regulation, or by relieving inhibition
of Ras signaling.
Both p19
Arf- and p53-deﬁcient papillomas displayed
several characteristics consistent with early malignancy.
Conversion of papillomas to carcinomas is ﬁrst characterized
by a ﬂattening, endophytic transition. p19
Arf- and p53-
deﬁcient papillomas had this morphology from the outset,
suggesting an early propensity for malignant conversion.
More detailed histological and immunochemical character-
ization showed that p53-deﬁcient papillomas were more
dysplastic and had aberrant expression of differentiation
markers such as E-cadherin, P-cadherin, and Keratin-13
(Cano et al. 1996). E-cadherin is a critical component of
cell–cell adhesion and its down regulation is strongly
associated with malignant progression (Birchmeier et al.
1993; Perl et al. 1998). That these ‘‘high risk’’ p53-null
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for a more direct effect of p53 on cellular phenotypes
associated with progression. In addition, there was a lack of
correlation between papilloma size and propensity to
progress. p53-null papillomas were fewer and smaller, yet
these showed the most rapid progression. Finally, metastasis
of skin tumors in both p19
Arf- and p53-deﬁcient mice was
observed within a matter of days after papilloma to
carcinoma conversion, again, irrespective of precursor tumor
size. Collectively, these data are inconsistent with a model in
which loss of p19
Arf or p53 indirectly accelerates tumor
progression by accelerating a series of independent genetic
events, each followed by clonal selection, and instead favor a
more direct model.
We suggest that Ras may be a major driving force for
multiple steps in tumor progression, with loss of p19
Arf and
p53 playing a facilitating role. In addition to the well-known
effects of Ras on proliferation, consistent with an early role in
neoplasia, Ras also contributes to a number of phenotypes
that are involved in malignant progression, including metas-
tasis. Ras induces cell motility, invasiveness (Lazarov et al.
2002; Dajee et al. 2003; Kim et al. 2003), epithelial to
mesenchymal transition (Oft et al. 1996; Zondag et al. 2000),
angiogenesis (Arbiser et al. 1997; Casanova et al. 2002), and
metastasis (Pozzatti et al. 1986; Webb et al. 1998; Oft et al.
2002; Varghese et al. 2002). Ras activates a number of
signaling cascades that drive these processes (Campbell et
al. 1998). For example, Ras activation of the Raf-MAPK
signaling cascade regulates the activities of nuclear tran-
scription factors, including AP-1 (Campbell et al. 1998). In
addition to regulating proliferation, AP-1 induces a motility/
invasion program (Ozanne et al. 2000; Jochum et al. 2001;
Young et al. 2003). Ras transgenic mice that lack Fos, a
component of AP-1, develop benign skin tumors, but these
fail to convert to carcinomas (Saez et al. 1995). MAPK
activation also determines the ability of Ras-transformed
ﬁbroblasts to metastasize to the lung (Webb et al. 1998).
Oncogenic Ras also works in concert with the Rho family of
GTPases to regulate the intracellular actin cytoskeleton and
promote cell motility and invasion leading to metastasis
(Zohn et al. 1998). Sustained signaling by oncogenic Ras can
permanently downregulate Rac activity and lead to an
epithelial to mesenchymal transition. This transition is
associated with changes in gene expression, loss of E-
cadherin-mediated cell–cell adhesions, and increased inva-
siveness of tumor cells (Oft et al. 1996, 2002; Zondag et al.
2000). This allows the cell to become mobile, invade
surrounding tissue, and establish metastatic sites. An addi-
tional link between Ras and tumor progression was demon-
strated in a genome-wide survey of Ras transformation
targets that identiﬁed a signiﬁcant increase in expression of
genes triggering invasion and metastasis, such as the laminin
receptor, collagenase (Mmp-1), stromolysin (Mmp-3), and the
Cd44 glycoprotein (Zuber et al. 2000). Ras also repressed
genes involved in anti-invasive or anti-angiogenic activity,
such as syndecan-2, tissue inhibitor of metalloproteases-2
(Timp-2), and thrombospondin-1.
Further support for a continual involvement of Ras in
tumor progression is indicated by the increase in copy
number of mutant Ras alleles that is observed during tumor
progression. In the DMBA/TPA skin tumor model, the mutant
Ras allele is frequently duplicated in papillomas and
ampliﬁed to multiple copies in carcinomas, especially in the
most aggressive spindle cell tumors (Bremner and Balmain
1990; Buchmann et al. 1991). Increased expression of mutant
Ras genes by gene ampliﬁcation or other mechanisms is
found in other tumor types (Schwab et al. 1983; Tanaka et al.
1986; Winter and Perucho 1986; Yokota et al. 1986) and has
been shown to promote the growth of head and neck SCC
and carcinoma of the cervix (Hoa et al. 2002; Soh et al. 2002).
This indicates that there is a selective advantage to
progressively increasing levels of Ras throughout tumor
progression. Quantitative differences in Ras activity are
known to differentially activate signaling pathways leading
to different cellular outcomes (Shields et al. 2000). Loss of p53
may facilitate the increase in Ras levels, in that cells with
inactivated p53 show greatly increased frequency of gene
ampliﬁcation (Yin et al. 1992).
Thus, mutation in Ras is much more than the initiating
event: it directly contributes to many of the phenotypes
associated with malignant progression (Figure 7). As Ras
induces both p19
Arf and p53, and both are antagonistic to
Ras, we suggest that an important consequence of p19
Arf and
p53 loss is that it permits increased Ras levels and signaling,
fueling further tumor progression. In addition to counter-
acting Ras, p19
Arf and p53 likely contribute to tumor
suppression through additional pathways. For example, loss
of p19
Arf increases tumor growth, and loss of p53 confers
resistance to apoptosis and loss of cell cycle checkpoints,
leading to genetic instability. The observation that oncogene
mutations are linked to tumor suppressor gene activation
through mechanistic signaling pathways indicates that selec-
tive pressure in favor of tumor suppressor gene mutations
originates from the initial oncogenic lesion and is thus
intrinsic to the tumor.
Figure 7. An Integrated Model of SCC Progression
At the genetic level, treatment of mouse skin with DMBA induces
mutations in Hras resulting in initiated cells that express constitu-
tively active Ras protein (grey rectangles). TPA treatment is required
for clonal expansion of these Hras mutant cells to form papillomas.
Frequent duplication of the mutant Ras allele in papillomas indicates
increased Ras signaling is favored. Mutation of p53, as well as
additional Ras gene ampliﬁcation, is seen in carcinomas, particularly
in the most aggressive tumors (black rectangles). At the signaling
level, mutant Ras upregulates p19
Arf (Arf), which in turn activates
p53. p19
Arf, in turn, inhibits growth of Hras-driven tumors in a p53-
independent manner. p19
Arf, acting through p53, also inhibits
malignant progression and metastasis. As Ras signals through p19
Arf
and p53, selection for subsequent mutations in p19
Arf or p53 is a
direct consequence of the initial Ras mutation. In this model, Ras
drives tumor progression through direct signaling effects and by
dictating the evolution pathway of the tumor.
DOI: 10.1371/journal.pbio.0020242.g007
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Mice. p19
Arf-deﬁcient mice (C57BL/6 3 129SvJ) were provided by
Martine Roussel and Charles Sherr (Kamijo et al. 1997). To increase
their susceptibility to skin tumor development, p19
Arf /  mice were
backcrossed to the susceptible NIH/Ola strain (Harlan Olac,
Oxfordshire, United Kingdom), and carcinogenesis studies were
performed on the F3 littermates of this cross. 20 mice of each
genotype, p19
Arf / , p19
Arfþ/ , and p19
Arfþ/þ were treated. The backs of
8-wk-old male and female mice were shaved and treated with a single
application of DMBA (25 lg in 200 ll of acetone; Sigma, St. Louis,
Missouri, United States) followed a week later by twice weekly
applications of TPA (200 llo f1 0
 4 M solution in acetone) for 15 wk.
The number and size of papillomas on each mouse were recorded
every 2 wk. Mice were sacriﬁced if moribund or following detection of
carcinomas. Tumors were frozen for DNA extraction and/or ﬁxed in
formalin to be processed and stained with hematoxylin/eosin (H&E)
for histological examination.
Mice deﬁcient for p53 (Donehower et al. 1992) (F7 backcross to
NIH) were crossed to p19
Arf-deﬁcient (F4 backcross to NIH) mice to
generate p19
Arfþ/ p53
þ/  mice. These mice were intercrossed to
generate all nine possible p19
Arf /p53 genotypes. Some 20–30 mice
of each genotype were subjected to the same DMBA/TPA protocol
and monitored as described above.
Immunoblotting. In order to remove abundant keratin present in
papillomas and carcinomas, nuclear extracts were prepared as
described (Schreiber et al. 1989) with modiﬁcations. Pieces of skin
or tumor were ground in liquid nitrogen with a mortar and pestle,
and the resulting powder was dissolved in buffer A and further
homogenized for 1 min on ice (PowerGen 125, Fischer Scientiﬁc,
Pittsburgh, Pennsylvania, United States). Buffers A and C both
contained 1 mM DTT, 0.4 mg/ml Pefablock, 25 mg/ml Aprotinin, 10
mg/ml Pepstatin, and 10 mg/ml leupeptin (Roche, Alameda, Califor-
nia, Unites States) to inhibit proteases. Protein concentrations were
standardized using the Bradford assay (Bio-Rad, Hercules, California,
United States) and equal loading (50 lg/lane) was conﬁrmed by
Ponceau S staining of the nylon membrane after blotting. Western
blot analysis was performed using speciﬁc antibodies against p19
Arf
(Novus Biologicals, Littleton, Colorado, United States) and p53
(Novocastra Laboratories, Newcastle-upon-Tyne, United Kingdom).
Hras sequencing. Genomic DNA was prepared from tumor and
normal tissue by QIAamp DNA Mini Kit (Qiagen, Valencia,
California, United States). A 400-bp PCR fragment containing exon
2o fHras was ampliﬁed with standard PCR (3.0 mM MgCl2
andannealing for 2 min at 37 8C with 40 cycles), with 59-
GACTCCTACCGGAAACAGGT-39 and 59-CTGTACTGATG-
GATGTCCTC-39 primers. We used the internal primer 59-
TGGTCATTGATGGGGAGACA-39 to sequence exon 2, using PE
Biosystems (Applied Biosystems, Foster City, Calfornia, United States)
Dye-Terminator and Big-Dye cycle sequencing.
Histological analysis. Sections of normal skin, papillomas, carci-
nomas, and other organs were removed and ﬁxed in 10% normal
buffered formalin for 4 h. After ﬁxation, tissues were processed and
then embedded in parafﬁn. From the tissues, 4-lm sections were cut
and stained for either p53 (CM5, Novocastra) or pan-keratin (AE1/
AE3, Novocastra) using high-temperature antigen retrieval in 10 mM
citrate buffer (pH 6), or for BrdU (Dako, Glostrup, Denmark) after
treating with 2N HCl followed by 0.1% trypsin. After staining with
the primary antibody, the sections were stained with a biotin-
conjugated secondary (Vector Laboratories, Burlingame, California,
United States) followed by StreptABComplex/HRP (Dako). Slides
were developed with DAB/NiCl and counterstained with methyl
green. Control sections with no primary antibody were run
concurrently. Other sections were cut and stained using a standard
H&E method. Proliferation index was determined by counting the
number of BrdU-stained cells per 403ﬁeld. The apoptotic index was
determined by counting the H&E slides for the number of apoptotic
ﬁgures per 403ﬁeld. All counts were done on a Nikon (Tokyo, Japan)
Labophot-2 microscope.
Semiquantitative PCR analysis. Genomic DNA was prepared from
tumor tissue or normal kidney by QIAamp DNA Mini Kit (Qiagen).
To measure LOH of the p19
Arf wild-type allele in p19
Arfþ/  tumors,
wild-type and knockout alleles were ampliﬁed by PCR separately then
combined for electrophoresis. Primers 59-AGTACAGCAGCGGGAG-
CATGG-39 (Arf1), 59-TTGAGGAGGACCGTGAAGCCG-39 (Arf2), and
59-ACCACACTGCTCGACATTGGG-39 (ArfN) were used to amplify
wild-type (Arf1 and Arf2) and knockout alleles (Arf2 and ArfN) from
100 ng of genomic DNA using 68 8C for annealing and extension at 90
s for 30 cycles. Equal amounts of each PCR product were then
combined for electrophoresis on a 2% TAE agarose gel. Wild-type
and knockout alleles of p53
þ/  tumors were ampliﬁed in a separate
reaction as described (Timme and Thompson 1994) for 30 cycles. PCR
products were electrophoresed on a 2% TAE agarose gel. Compar-
ison gradients for p19
Arf and p53 were established by combining wild-
type and knockout genomic DNA in quantiﬁed ratios, then
amplifying as described above.
Statistical methods. In order to assess the impact of p19
Arf (or
p19
Arf /p53) genotypes on the development of papillomas, longitudinal
proﬁles of papilloma counts were analyzed using the generalized
estimating equation (GEE) approach (Zeger and Liang 1986). GEE is
an established statistical approach to the regression analysis of
longitudinal data. Our analysis used papilloma counts of each mouse
measured every 2 wk as the outcome variable and incorporated
within-mouse correlations of papilloma counts over time in making
statistical inference. Using GEE, we estimated average differences of
papilloma counts across genotypes after DMBA administration. Since
the development of papillomas depends on the time since the DMBA
administration and may differ by the sex of the mice, the effects of
the weeks since the DMBA administration and sex were controlled for
in the GEE analysis as covariates. A working correlation structure of
the GEE analysis was speciﬁed as the ﬁrst-order autoregressive
structure over the time since the DMBA administration; however,
GEE is robust against the misspeciﬁcation of the correlation
structure. In contrast to papillomas, the overall number of
carcinomas developed during the experiment was relatively small.
Thus, we analyzed differences by genotype in the probability of
developing a carcinoma after DMBA administration. A logistic
regression model (Clayton and Hills 2003) was used to assess the
odds of developing a carcinoma during the experimental period and
to compare it across p19
Arf (or p19
Arf /p53) genotypes. Estimates of
relative odds were adjusted for sex effects. Fisher’s exact test was used
for comparing two proportions such as comparing LOH proportions
between papillomas and carcinomas. All statistical tests were two-
sided.
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